About Perdaman Pharmaceuticals Private Limited
Data last updated:
Perdaman Pharmaceuticals Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 04 March 2008 and has been in existence for over 18 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24233DL2008PTC174864. Its GSTIN is 07AAFCP5941H1ZA (Delhi). The company holds 3 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹15 Cr and a paid-up capital of ₹12.03 Cr. It was formerly known as Perdaman Financial Services and Holdings Private Limited. It is led by directors including Vikas Rambal and Manoj Kumar Rambal.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2024. The registered office is at N – 9 Ground Floor Panchsheel Park, New Delhi, Delhi, India – 110017.
As per the financials filed for FY 2025, the company reported a revenue of ₹28.76 Cr, a growth of 4% compared to the previous year. For the same year it recorded a net profit of ₹21.85 Lakh (net margin 0.8%) and EBITDA of ₹2.63 Cr (EBITDA margin 9.1%). Revenue has grown at a compounded annual rate (CAGR) of 1% over three years and 10% over five years.
Its group structure includes 1 subsidiary.
The company is associated with 1 brand: Sunrise International Labs. The company has 6 deals on record (4 secondary share transfers, 1 funding round, 1 rights issue), with disclosed funding of ₹9.99 Cr; the latest was in July 2018. Its 3 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (wholesale trading) are compared by revenue, 3 larger; the largest is Prowell Lifesciences Private Limited with revenue of ₹28.95 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website perdaman.com.au.
Company details
CIN history
Perdaman Pharmaceuticals has one previous CIN (Corporate Identification Number): U65910DL2008PTC174864. The current CIN is U24233DL2008PTC174864, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24233DL2008PTC174864 | Current |
| U65910DL2008PTC174864 | Previous |
Contact details
Perdaman Pharmaceuticals Private Limited's registered office is in New Delhi, Delhi. Its website is perdaman.com.au. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressN – 9 Ground Floor Panchsheel Park, New Delhi, Delhi, India – 110017
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Perdaman Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Perdaman Pharmaceuticals operates one associated brand: Sunrise International Labs. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Specializes in branded generics, formulations, and OTC drugs for pharmaceutical markets. | sunriseinternationallabs.com |
Business activity
The main business activity of Perdaman Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Perdaman Pharmaceuticals Private Limited, buy the company report.
Financials of Perdaman Pharmaceuticals Private Limited
FY 2024 filings availablePerdaman Pharmaceuticals Private Limited reported revenue of ₹28.76 Cr (up 4% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 10% over five years, including 4% growth in the latest year. EBITDA fell 1% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹2.63 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹21.85 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 9.1% | ||||
| Net Profit Margin | 0.8% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Perdaman Pharmaceuticals Private Limited, buy the company report.
Board of directors of Perdaman Pharmaceuticals Private Limited
Perdaman Pharmaceuticals has 5 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Vikas Rambal Also directs: Shirdi Bio Fuels Private Limited, Sunrise International Labs Limited, Perdaman Renewable Energy Private Limited and 3 more | Director | 01 Dec 2015 | 10 Years 10 Months | Current |
| Manoj Kumar Rambal Also directs: Sunrise International Labs Limited | Director | 15 May 2010 | 16 Years 5 Months | Current |
| Usha Rambal | Director | 14 Oct 2010 | 16 Years 0 Months | Current |
| Samir Madhukar Garud Also directs: Sunrise International Labs Limited | Director | 20 Jun 2013 | 13 Years 4 Months | Current |
| Sarojni Rambal Also directs: Shirdi Bio Fuels Private Limited | Director | 24 Jan 2017 | 9 Years 8 Months | Current |
Peer comparison
Perdaman Pharmaceuticals Private Limited is compared with the 3 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Prowell Lifesciences Private Limited | ₹28.95 Cr (FY 2025) | 101.0% | Faridabad, Haryana, India | |||
| Stantech Pharmaceuticals Private Limited | ₹28.91 Cr (FY 2024) | 17.0% | Mumbai, Maharashtra, India | |||
| Dycine Pharmaceuticals Limited | ₹28.83 Cr (FY 2025) | 6.0% | Noida, Uttar Pradesh, India | |||
| Perdaman Pharmaceuticals Private Limitedthis company | ₹28.76 Cr (FY 2025) | ₹21.85 Lakh | 0.8% | 4.0% | New Delhi, Delhi, India |
To see the full peer comparison of Perdaman Pharmaceuticals Private Limited, buy the company report.
Auditor
Perdaman Pharmaceuticals Private Limited is audited by Lavlesh & Associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Lavlesh & Associates | FY 2023 | 021978N |
Shareholding
The shareholding of Perdaman Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Perdaman Pharmaceuticals Private Limited, buy the company report.
Deals & funding
Perdaman Pharmaceuticals Private Limited has 6 deals on record (4 secondary share transfers, 1 funding round, 1 rights issue), with disclosed funding of ₹9.99 Cr; the latest was in July 2018.
Deals on record (5 of 6)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jul 2018 | Rights issue | ₹2.03 Cr | Investors: Global Tech Consulting & Trading Pte Limited |
| Dec 2015 | Secondary share transfer | Undisclosed | Buyer: Tulmul Family Trust Seller: an individual |
| Oct 2015 | Secondary share transfer | Undisclosed | Buyer: Tulmul Family Trust Seller: an individual |
| Sep 2015 | Secondary share transfer | Undisclosed | Buyer: Tulmul Family Trust Seller: an individual |
| Jul 2013 | Funding round | ₹9.99 Cr | Investors: 3 individuals |
To see the full deal history of Perdaman Pharmaceuticals Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Perdaman Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Perdaman Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Group structure & subsidiaries
Perdaman Pharmaceuticals has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Sunrise International Labs Limited | U24239TG1993PLC015367 |
To see the full group structure of Perdaman Pharmaceuticals Private Limited, buy the company report.
GST
Perdaman Pharmaceuticals has 3 GST registrations: 1 active and 2 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAFCP5941H1ZA | Delhi | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Perdaman Pharmaceuticals Private Limited, buy the company report.
Recent activity
Perdaman Pharmaceuticals Private Limited has 9 board changes on record since 2010: 5 appointments and 4 cessations. The latest: Manish Kumar Gupta ceased to be Company Secretary on 31 May 2022.
Frequently asked questions
Perdaman Pharmaceuticals is an active private limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 04 March 2008 (18+ years old) and is registered under CIN U24233DL2008PTC174864.
Perdaman Pharmaceuticals has 5 current directors:
- Vikas Rambal - Director
- Manoj Kumar Rambal - Director
- Usha Rambal - Director
- Samir Madhukar Garud - Director
- Sarojni Rambal - Director
The latest financial statements of Perdaman Pharmaceuticals on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Perdaman Pharmaceuticals is 07AAFCP5941H1ZA, registered in Delhi. The company has 3 GST registrations in all, of which 1 is active and 2 are cancelled or inactive.
The CIN (Corporate Identification Number) of Perdaman Pharmaceuticals is U24233DL2008PTC174864. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Perdaman Pharmaceuticals was incorporated on 04 March 2008, making it 18+ years old. It is registered with the Registrar of Companies, Delhi.
Perdaman Pharmaceuticals has 6 deals on record (4 secondary share transfers, 1 funding round, 1 rights issue), with disclosed funding of ₹9.99 Cr; the latest was in July 2018.
The peers of Perdaman Pharmaceuticals by revenue are Prowell Lifesciences Private Limited, Stantech Pharmaceuticals Private Limited, Dycine Pharmaceuticals Limited, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (wholesale trading).
Manish Kumar Gupta ceased to be Company Secretary on 31 May 2022. Sarojni Rambal was appointed as Director on 24 Jan 2017. Indeevar Kaul ceased to be Director on 01 Jan 2017. Perdaman Pharmaceuticals has 9 board changes on record in total.
Perdaman Pharmaceuticals can be reached through the website perdaman.com.au. Its registered office is in New Delhi, Delhi, India.
The registered office of Perdaman Pharmaceuticals is at N – 9 Ground Floor Panchsheel Park, New Delhi, Delhi, India – 110017.